Nicolas Barry Delongchamps,Alexandre Peltier,Eric Potiron,Franck Bladou,Romain Diamand,Aurel Messas,Jean-Baptiste Roche,Grégoire Robert,Jean-Louis Hoepffner,Thierry Piechaud,Julien Anract,Roland van Velthoven
OBJECTIVETo assess the oncological outcomes of targeted microwave ablation (TMA) using organ-based tracking (OBT) Fusion® via KOELIS Trinity® (KOELIS, Meylan, France) in men with intermediate-risk prostate cancer (PCa): the VIOLETTE trial (ClinicalTrials.gov identifier: NCT04582656) PATIENTS AND METHOD: In this prospective phase II, multicentre European study, men with a prostate-specific antigen (PSA) level <20 ng/mL, a single magnetic resonance imaging (MRI)-visible lesion ≤15 mm, International Society of Urological Pathology (ISUP) Grade Group 2 on MRI-targeted biopsy, and clinical T stage ≤2, were enrolled. The microwave applicator was placed using OBT Fusion guidance, either transperineally or transrectally. The primary endpoint was the absence of clinically significant PCa (csPCa), defined as ISUP Grade Group ≥2, within the treated area at 12 months. Secondary endpoints included safety, functional outcomes using validated measures, and the need for subsequent radical treatment.RESULTSA total of 76 patients were treated across six centres with 66 (87%) completing the 12-month follow-up. At 6 months, six patients had csPCa after positive MRI control, including four within the treated area. At 12 months, csPCa was detected in 15 additional patients, including nine in-field recurrences, yielding an 81% in-field csPCa-free rate. Five serious adverse events in three patients were reported. Sexual (-2.5 points; P < 0.001) and ejaculatory (-1 points; P < 0.001) scores decreased significantly, whereas urinary function remained stable. Radical treatment was required in four (5.2%) patients at 12 months.CONCLUSIONTargeted microwave ablation using OBT Fusion technology appears to be a safe and effective focal therapy procedure for localised intermediate-risk PCa. The VIOLETTE trial achieved its primary endpoint, with 81% patients free of in-field csPCa at 12 months.
{"title":"Targeted microwave ablation of localised prostate cancer (VIOLETTE trial): a prospective multicentre study.","authors":"Nicolas Barry Delongchamps,Alexandre Peltier,Eric Potiron,Franck Bladou,Romain Diamand,Aurel Messas,Jean-Baptiste Roche,Grégoire Robert,Jean-Louis Hoepffner,Thierry Piechaud,Julien Anract,Roland van Velthoven","doi":"10.1111/bju.70220","DOIUrl":"https://doi.org/10.1111/bju.70220","url":null,"abstract":"OBJECTIVETo assess the oncological outcomes of targeted microwave ablation (TMA) using organ-based tracking (OBT) Fusion® via KOELIS Trinity® (KOELIS, Meylan, France) in men with intermediate-risk prostate cancer (PCa): the VIOLETTE trial (ClinicalTrials.gov identifier: NCT04582656) PATIENTS AND METHOD: In this prospective phase II, multicentre European study, men with a prostate-specific antigen (PSA) level <20 ng/mL, a single magnetic resonance imaging (MRI)-visible lesion ≤15 mm, International Society of Urological Pathology (ISUP) Grade Group 2 on MRI-targeted biopsy, and clinical T stage ≤2, were enrolled. The microwave applicator was placed using OBT Fusion guidance, either transperineally or transrectally. The primary endpoint was the absence of clinically significant PCa (csPCa), defined as ISUP Grade Group ≥2, within the treated area at 12 months. Secondary endpoints included safety, functional outcomes using validated measures, and the need for subsequent radical treatment.RESULTSA total of 76 patients were treated across six centres with 66 (87%) completing the 12-month follow-up. At 6 months, six patients had csPCa after positive MRI control, including four within the treated area. At 12 months, csPCa was detected in 15 additional patients, including nine in-field recurrences, yielding an 81% in-field csPCa-free rate. Five serious adverse events in three patients were reported. Sexual (-2.5 points; P < 0.001) and ejaculatory (-1 points; P < 0.001) scores decreased significantly, whereas urinary function remained stable. Radical treatment was required in four (5.2%) patients at 12 months.CONCLUSIONTargeted microwave ablation using OBT Fusion technology appears to be a safe and effective focal therapy procedure for localised intermediate-risk PCa. The VIOLETTE trial achieved its primary endpoint, with 81% patients free of in-field csPCa at 12 months.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"19 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147383600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Raimundo Domínguez Argomedo,Pedro de Pablos-Rodríguez,Alicia Palop Moscardó,Álvaro Gómez-Ferrer Lozano,Isidora Calvo Bernasconi,Juan Luis Casanova Ramón-Borja,Argimiro Collado Serra
OBJECTIVESTo evaluate the correlation between the pad-per-day (PPD) count and the 24-h pad test (24 h-PT) during the first postoperative year after radical prostatectomy (RP), and to determine the clinical utility of the PPD count for quantitative urinary incontinence (UI) assessment.PATIENTS AND METHODSWe retrospectively analysed a prospectively maintained database of 2040 men who underwent RP between 2001 and 2025 at a tertiary referral centre. A total of 8787 paired measurements of PPD count and 24 h-PT were analysed. Urinary leakage was assessed at standardised timepoints (1 week, 6 weeks, 3, 6, and 12 months) using count of PPD and nurse-supervised 24 h-PT. UI severity was classified as mild (<100 g), moderate (100-400 g), or severe (>400 g). Correlations were calculated using Spearman's ρ.RESULTSThe correlation between the PPD count and 24 h-PT was strong across all timepoints and increased over the postoperative year, from ρ = 0.77 at 1 week to 0.99 at 12 months. The overall correlation for all paired measurements was ρ = 0.94 (95% confidence interval 0.93-0.94). The median (interquartile range) 24 h-PT values rose consistently with increasing PPD count categories: from 15 (7-38) g for 1 pad/day to 781 (478-1200) g for ≥5 pads/day. At 12 months, 94% of men using one pad had urine loss <100 g, whereas 85% of those using ≥5 pads/day exceeded 400 g. Intermediate categories (2-4 pads/day) showed wide variability, limiting their discriminative value.CONCLUSIONSThe PPD count shows a strong correlation with 24 h-PT throughout the first postoperative year after RP. Use of 0-1 pad/day effectively excluded moderate-to-severe UI, whereas ≥5 pads/day reliably identified severe UI. The PPD count is a practical follow-up tool, while 24 h-PT remains necessary for patients using 2-4 pads/day.
{"title":"The 24-h pad test in the assessment of post-prostatectomy incontinence: is there still a role for counting pads per day?","authors":"Raimundo Domínguez Argomedo,Pedro de Pablos-Rodríguez,Alicia Palop Moscardó,Álvaro Gómez-Ferrer Lozano,Isidora Calvo Bernasconi,Juan Luis Casanova Ramón-Borja,Argimiro Collado Serra","doi":"10.1111/bju.70224","DOIUrl":"https://doi.org/10.1111/bju.70224","url":null,"abstract":"OBJECTIVESTo evaluate the correlation between the pad-per-day (PPD) count and the 24-h pad test (24 h-PT) during the first postoperative year after radical prostatectomy (RP), and to determine the clinical utility of the PPD count for quantitative urinary incontinence (UI) assessment.PATIENTS AND METHODSWe retrospectively analysed a prospectively maintained database of 2040 men who underwent RP between 2001 and 2025 at a tertiary referral centre. A total of 8787 paired measurements of PPD count and 24 h-PT were analysed. Urinary leakage was assessed at standardised timepoints (1 week, 6 weeks, 3, 6, and 12 months) using count of PPD and nurse-supervised 24 h-PT. UI severity was classified as mild (<100 g), moderate (100-400 g), or severe (>400 g). Correlations were calculated using Spearman's ρ.RESULTSThe correlation between the PPD count and 24 h-PT was strong across all timepoints and increased over the postoperative year, from ρ = 0.77 at 1 week to 0.99 at 12 months. The overall correlation for all paired measurements was ρ = 0.94 (95% confidence interval 0.93-0.94). The median (interquartile range) 24 h-PT values rose consistently with increasing PPD count categories: from 15 (7-38) g for 1 pad/day to 781 (478-1200) g for ≥5 pads/day. At 12 months, 94% of men using one pad had urine loss <100 g, whereas 85% of those using ≥5 pads/day exceeded 400 g. Intermediate categories (2-4 pads/day) showed wide variability, limiting their discriminative value.CONCLUSIONSThe PPD count shows a strong correlation with 24 h-PT throughout the first postoperative year after RP. Use of 0-1 pad/day effectively excluded moderate-to-severe UI, whereas ≥5 pads/day reliably identified severe UI. The PPD count is a practical follow-up tool, while 24 h-PT remains necessary for patients using 2-4 pads/day.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"18 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147394015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gavin G Calpin,Cian M Hehir,Mariyah Alzayer,Benjamin M MacCurtain,Fintan R Ryan,Mohammud Shakeel Inder,Diarmaid C Moran,David J Galvin,Kieran J Breen
OBJECTIVETo compare transrectal ultrasonography (TRUS) and local anaesthetic transperineal (LATP) biopsy.METHODSA systematic review of randomised control trials and prospective studies meeting eligibility criteria was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.RESULTSA total of 12 studies with 8497 patients were included. LATP biopsy was performed in 3961 patients and TRUS biopsy in 4536. Patient characteristics were comparable in both groups. Infection (risk ratio [RR] 0.68, 95% confidence interval [CI] 0.56-0.84, P < 0.001) and sepsis rates were significantly lower in the LATP group (RR 0.16, 95% CI 0.08-0.33, P < 0.001) and urinary retention rates were comparable (RR 0.87, 95% CI 0.61-1.25, P = 0.46). Overall cancer detection rates were significantly higher in LATP biopsy (RR 1.07, 95% CI 1.03-1.10, P < 0.001) as were Gleason Grade Group 2-5 or clinically significant cancer detection rates (RR 1.12, 95% CI 1.06-1.18, P < 0.001). Gleason GG 1 detection rates were comparable (RR 0.92, 95% CI 0.82-1.04, P = 0.20).CONCLUSIONThe LATP biopsy is associated with lower rates of infection and sepsis compared to TRUS biopsy. The LATP biopsy also detects a higher overall incidence of prostate cancer and clinically significant prostate cancer (Gleason Grade Group 2-5).
目的比较经直肠超声检查（TRUS）与经会阴局麻活检（LATP）的临床疗效。方法按照系统评价和荟萃分析指南的首选报告项目，对符合入选标准的随机对照试验和前瞻性研究进行系统评价。结果共纳入12项研究，8497例患者。3961例患者行LATP活检，4536例行TRUS活检。两组患者的特征具有可比性。LATP组感染（危险比[RR] 0.68, 95%可信区间[CI] 0.56 ~ 0.84, P < 0.001）和脓毒症发生率显著降低（RR 0.16, 95% CI 0.08 ~ 0.33, P < 0.001），尿潴留率相当（RR 0.87, 95% CI 0.61 ~ 1.25, P = 0.46）。LATP活检的总体癌症检出率（RR 1.07, 95% CI 1.03-1.10, P < 0.001）显著高于Gleason分级2-5组或具有临床意义的癌症检出率（RR 1.12, 95% CI 1.06-1.18, P < 0.001）。Gleason GG 1检出率具有可比性（RR 0.92, 95% CI 0.82 ~ 1.04, P = 0.20）。结论与TRUS活检相比，LATP活检与较低的感染和败血症发生率相关。LATP活检也能检测到更高的前列腺癌总发病率和具有临床意义的前列腺癌（Gleason分级2-5组）。
{"title":"Transrectal vs transperineal prostate biopsy: a systematic review and meta-analysis.","authors":"Gavin G Calpin,Cian M Hehir,Mariyah Alzayer,Benjamin M MacCurtain,Fintan R Ryan,Mohammud Shakeel Inder,Diarmaid C Moran,David J Galvin,Kieran J Breen","doi":"10.1111/bju.70204","DOIUrl":"https://doi.org/10.1111/bju.70204","url":null,"abstract":"OBJECTIVETo compare transrectal ultrasonography (TRUS) and local anaesthetic transperineal (LATP) biopsy.METHODSA systematic review of randomised control trials and prospective studies meeting eligibility criteria was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.RESULTSA total of 12 studies with 8497 patients were included. LATP biopsy was performed in 3961 patients and TRUS biopsy in 4536. Patient characteristics were comparable in both groups. Infection (risk ratio [RR] 0.68, 95% confidence interval [CI] 0.56-0.84, P < 0.001) and sepsis rates were significantly lower in the LATP group (RR 0.16, 95% CI 0.08-0.33, P < 0.001) and urinary retention rates were comparable (RR 0.87, 95% CI 0.61-1.25, P = 0.46). Overall cancer detection rates were significantly higher in LATP biopsy (RR 1.07, 95% CI 1.03-1.10, P < 0.001) as were Gleason Grade Group 2-5 or clinically significant cancer detection rates (RR 1.12, 95% CI 1.06-1.18, P < 0.001). Gleason GG 1 detection rates were comparable (RR 0.92, 95% CI 0.82-1.04, P = 0.20).CONCLUSIONThe LATP biopsy is associated with lower rates of infection and sepsis compared to TRUS biopsy. The LATP biopsy also detects a higher overall incidence of prostate cancer and clinically significant prostate cancer (Gleason Grade Group 2-5).","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"40 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147374109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alexander B C D Ng,Quentin Mak,Aqua Asif,Alexander Light,Aishwarya Shah,Ranya V Kumar,Molly M Nichols,Ahaduzzaman Khan,Pranav Satish,Gozde Gutelkin,Katherine Wise,Ben Ayres,Stephanie F Smith,Kevin G Byrnes,Arjun Nathan,Veeru Kasivisvanathan
{"title":"Defining a new national undergraduate urology curriculum in the UK using consensus-based methodology.","authors":"Alexander B C D Ng,Quentin Mak,Aqua Asif,Alexander Light,Aishwarya Shah,Ranya V Kumar,Molly M Nichols,Ahaduzzaman Khan,Pranav Satish,Gozde Gutelkin,Katherine Wise,Ben Ayres,Stephanie F Smith,Kevin G Byrnes,Arjun Nathan,Veeru Kasivisvanathan","doi":"10.1111/bju.70216","DOIUrl":"https://doi.org/10.1111/bju.70216","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"29 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147371030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alice Thomson,Arthur Yim,Kirby Qin,Damien Bolton,Peter Liodakis
OBJECTIVETo investigate the temporal changes in lower urinary tract symptoms (LUTS) following transurethral resection of prostate (TURP), assessed using fortnightly completion of the International Prostate Symptom Score (IPSS) as compared to baseline.PATIENTS AND METHODSThis was a prospective observational study. Patients completed the IPSS preoperatively and at 2, 4, 6 and 8 weeks postoperatively. Age, body mass index, prior TURP, resected prostate mass, histology, analgesia, symptomatic urinary tract infections (UTIs), and unplanned readmissions were also collected.RESULTSA total of 50 men were enrolled in the study with a mean (SD, range) age of 70.1 (8.4, 47-95) years. The mean (SD) baseline IPSS was 25.5 (7.9) points, indicating severe symptoms in majority of patients. Significant improvement was observed across all timepoints (P < 0.001 for all comparisons vs baseline, repeated measures analysis of variance). Irritative symptoms saw an immediate improvement at 2 weeks compared to baseline, which was sustained until final follow up. Quality of life improved by 56% and was moderately correlated with frequency (r = 0.68), weak stream (r = 0.63) and nocturia (r = 0.61). Both resected prostate mass and age displayed poor correlation with IPSS symptoms (r = -0.09 to -0.36 and 0.01 to 0.22 respectively). Analgesia (patient-reported paracetamol or ibuprofen) use decreased over time to 34%, 16%, 12%, and 8% at 2, 4, 6, and 8 weeks respectively. Antibiotics for UTI were given in 14% of patients, whilst 5% required re-admission due to clot retention.CONCLUSIONContrary to common clinician expectations, LUTS did not worsen in the initial postoperative period. Quality-of-life scores correlated with a mixture of irritative and obstructive symptoms. These findings now quantify expected rates of improvement postoperatively and allow for further investigation into tailored interventions such as pharmacotherapy to enhance patient experience and outcomes.
{"title":"Natural history of lower urinary tract symptoms following transurethral resection of prostate: a prospective observational study.","authors":"Alice Thomson,Arthur Yim,Kirby Qin,Damien Bolton,Peter Liodakis","doi":"10.1111/bju.70219","DOIUrl":"https://doi.org/10.1111/bju.70219","url":null,"abstract":"OBJECTIVETo investigate the temporal changes in lower urinary tract symptoms (LUTS) following transurethral resection of prostate (TURP), assessed using fortnightly completion of the International Prostate Symptom Score (IPSS) as compared to baseline.PATIENTS AND METHODSThis was a prospective observational study. Patients completed the IPSS preoperatively and at 2, 4, 6 and 8 weeks postoperatively. Age, body mass index, prior TURP, resected prostate mass, histology, analgesia, symptomatic urinary tract infections (UTIs), and unplanned readmissions were also collected.RESULTSA total of 50 men were enrolled in the study with a mean (SD, range) age of 70.1 (8.4, 47-95) years. The mean (SD) baseline IPSS was 25.5 (7.9) points, indicating severe symptoms in majority of patients. Significant improvement was observed across all timepoints (P < 0.001 for all comparisons vs baseline, repeated measures analysis of variance). Irritative symptoms saw an immediate improvement at 2 weeks compared to baseline, which was sustained until final follow up. Quality of life improved by 56% and was moderately correlated with frequency (r = 0.68), weak stream (r = 0.63) and nocturia (r = 0.61). Both resected prostate mass and age displayed poor correlation with IPSS symptoms (r = -0.09 to -0.36 and 0.01 to 0.22 respectively). Analgesia (patient-reported paracetamol or ibuprofen) use decreased over time to 34%, 16%, 12%, and 8% at 2, 4, 6, and 8 weeks respectively. Antibiotics for UTI were given in 14% of patients, whilst 5% required re-admission due to clot retention.CONCLUSIONContrary to common clinician expectations, LUTS did not worsen in the initial postoperative period. Quality-of-life scores correlated with a mixture of irritative and obstructive symptoms. These findings now quantify expected rates of improvement postoperatively and allow for further investigation into tailored interventions such as pharmacotherapy to enhance patient experience and outcomes.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"6 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147373954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Francesco Chierigo, Giuseppe Fallara, Marco Tozzi, Andrea Salonia, Matteo Ferro, Hussain M Alnajjar, Asif Muneer, Karl H Pang
Objective: To compare major Peyronie's disease (PD) guidelines, highlight key similarities and differences among panel recommendations, and identify areas requiring further research.
Methods: An extensive review was conducted to analyse and compare diagnostic and treatment recommendations from publicly available guidelines published by the American Urological Association, European Association of Urology, Canadian Urological Association, and the International Society of Sexual Medicine. Key similarities and differences regarding PD definition, evaluation, non-surgical treatments, and surgical management were systematically compared.
Results: Areas of general consensus across guidelines include the importance of comprehensive history-taking for PD diagnosis and the role of intracavernosal injection as the 'gold standard' for assessing penile deformity prior to invasive intervention. Shared decision-making and thorough patient counselling are universally emphasised. Plication or incision and grafting surgery is generally reserved for patients with preserved erectile function, whereas penile prosthesis implantation is the preferred surgical option for those with erectile dysfunction unresponsive to medical therapy. Non-surgical treatments remain an area of controversy due to limited evidence of efficacy; however, intralesional injections are recognised by all panels as a potential treatment option, especially in the acute phase. Further research into PD pathophysiology and rigorous outcomes studies are needed to inform novel treatments and refine surgical management strategies.
Conclusion: While major urological societies demonstrate substantial consensus on several aspects of PD evaluation and management, key areas of divergence remain, underscoring the need for further research to guide evidence-based care.
{"title":"Guideline of guidelines: Peyronie's disease.","authors":"Francesco Chierigo, Giuseppe Fallara, Marco Tozzi, Andrea Salonia, Matteo Ferro, Hussain M Alnajjar, Asif Muneer, Karl H Pang","doi":"10.1111/bju.70201","DOIUrl":"https://doi.org/10.1111/bju.70201","url":null,"abstract":"<p><strong>Objective: </strong>To compare major Peyronie's disease (PD) guidelines, highlight key similarities and differences among panel recommendations, and identify areas requiring further research.</p><p><strong>Methods: </strong>An extensive review was conducted to analyse and compare diagnostic and treatment recommendations from publicly available guidelines published by the American Urological Association, European Association of Urology, Canadian Urological Association, and the International Society of Sexual Medicine. Key similarities and differences regarding PD definition, evaluation, non-surgical treatments, and surgical management were systematically compared.</p><p><strong>Results: </strong>Areas of general consensus across guidelines include the importance of comprehensive history-taking for PD diagnosis and the role of intracavernosal injection as the 'gold standard' for assessing penile deformity prior to invasive intervention. Shared decision-making and thorough patient counselling are universally emphasised. Plication or incision and grafting surgery is generally reserved for patients with preserved erectile function, whereas penile prosthesis implantation is the preferred surgical option for those with erectile dysfunction unresponsive to medical therapy. Non-surgical treatments remain an area of controversy due to limited evidence of efficacy; however, intralesional injections are recognised by all panels as a potential treatment option, especially in the acute phase. Further research into PD pathophysiology and rigorous outcomes studies are needed to inform novel treatments and refine surgical management strategies.</p><p><strong>Conclusion: </strong>While major urological societies demonstrate substantial consensus on several aspects of PD evaluation and management, key areas of divergence remain, underscoring the need for further research to guide evidence-based care.</p>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comment on 'Adverse in-hospital outcomes in patients with paraplegia who undergo radical prostatectomy'.","authors":"Longtu Ma,Rui Lu,Zhilong Dong","doi":"10.1111/bju.70209","DOIUrl":"https://doi.org/10.1111/bju.70209","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"1 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147359072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reply to 'Comment on novel MRI-US fusion with advanced annotation in focal cryoablation for prostate cancer'.","authors":"Alessandro Marquis,Ardeshir R Rastinehad","doi":"10.1111/bju.70198","DOIUrl":"https://doi.org/10.1111/bju.70198","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"1 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147359073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：